Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364053 | 0.92 | CHRNB4 (0.30) | NPSR1 | |
| SCHEMBL19934115 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2NPSR1CYP2C9CYP2C19OGA | |
| SCHEMBL21238478 | 0.81 | MAPK1 (0.30) | — | |
| SCHEMBL20687623 | 0.81 | MAPK1 (0.30) | — | |
| SCHEMBL20688104 | 0.81 | MAPK1 (0.30) | — | |
| SCHEMBL21238475 | 0.81 | MAPK1 (0.30) | — | |
| SCHEMBL21227366 | 0.81 | MAPK1 (0.30) | — | |
| SCHEMBL19934117 | 0.80 | CYP1A2 (0.40) | SMN1; SMN2NPSR1CYP2C9CYP2C19OGA | |
| SCHEMBL21343054 | 0.80 | CYP1A2 (0.46) | SMN1; SMN2NPSR1 | |
| SCHEMBL16123034 | 0.79 | FGFR4 (0.37) | CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405887-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405887-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | SMN1; SMN2 3628/4885NPSR1 2632/4885CYP2C9 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.